Anecdotal reports and preliminary studies suggest a therapeutic potential of cannabis in Tourette syndrome. We report the case of a female patient suffering from treatment-resistant Tourette syndrome.
Methods
Guideline-directed antipsychotic treatment with risperidone and aripiprazole as well as pure delta-9-tetrahydrocannabinol had no significant effect on Tourette syndrome symptomatology.
Results
Following administration of a daily dosage of 10 mg delta-9-tetrahydrocannabinol combined with 20 mg cannabidiol (CBD), the patient showed a rapid and highly significant improvement in the Yale Global Tic Severity Scale.
Conclusions
It can be speculated whether the beneficial effects may rely on the pharmacological properties of cannabidiol.
ScharfJMMillerLLMathewsCAet al.
Prevalence of Tourette syndrome and chronic tics in the population-based Avon longitudinal study of parents and children cohort. J Am Acad Child Adolesc Psychiatry2012;
51: 192–201.
2.
ApterAPaulsDLBleichAet al.
An epidemiologic study of Gilles de la Tourette’s syndrome in Israel. Arch Gen Psychiatry1993;
50: 734–738.
3.
GanosCRoessnerVMunchauA.The functional anatomy of Gilles de la Tourette syndrome. Neurosci Biobehav Rev2013;
37: 1050–1062.
4.
PaschouP.The genetic basis of Gilles de la Tourette Syndrome. Neurosci Biobehav Rev2013;
37: 1026–1039.
5.
GormanDAAbi-JaoudeE.Uncovering the complexity of Tourette syndrome, little by little. Br J Psychiatry2014;
204: 6–8.
6.
AlbinRLMinkJW.Recent advances in Tourette syndrome research. Trends Neurosci2006;
29: 175–182.
7.
WylieSAClaassenDOKanoffKEet al.
Impaired inhibition of prepotent motor actions in patients with Tourette syndrome. J Psychiatry Neurosci2013;
38: 349–356.
8.
KawohlWBrühlAKrowatschekGet al.
Functional magnetic resonance imaging of tics and tic suppression in Gilles de la Tourette syndrome. World J Biol Psychiatry2009;
10: 567–570.
9.
RoessnerVPlessenKJRothenbergerAet al.
European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry2011;
20: 173–196.
10.
NeunerINordtCSchneiderFet al.
Effectiveness of aripiprazole in the treatment of adult Tourette patients up to 56 months. Hum Psychopharmacol2012;
27: 364–369.
11.
KawohlWSchneiderFVernalekenIet al.
Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients. World J Biol Psychiatry2009;
10: 827–831.
12.
Müller-VahlKR.Treatment of Tourette syndrome with cannabinoids. Behav Neurol2013;
27: 119–124.
13.
PertweeRG.The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol2008;
153: 199–215.
14.
GlassMDragunowMFaullRL.Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience1997;
77: 299–318.
15.
LeckmanJFRiddleMAHardinMTet al.
The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry1989;
28: 566–573.
16.
Baron-CohenSWheelwrightS.The empathy quotient: an investigation of adults with Asperger syndrome or high functioning autism, and normal sex differences. J Autism Dev Disord2004;
34: 163–175.
17.
BrunnauerASegmüllerFMVolkamerTet al.
Cannabinoids improve driving ability in a Tourette’s patient. Psychiatry Res2011;
190: 382
18.
HasanARothenbergerAMünchauAet al.
Oral delta-9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. J Clin Psychopharmacol2010;
30: 190–192.
19.
HemmingMYellowleesPM.Effective treatment of Tourette’s syndrome with marijuana. J Psychopharmacol1993;
7: 389–391.
20.
Müller-VahlKRSchneiderUKolbeHet al.
Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry1999;
156: 495
21.
SandykRAwerbuchG.Marijuana and Tourette’s syndrome. J Clin Psychopharmacol1988;
8: 444–445.
22.
Müller-VahlKRSchneiderUKoblenzAet al.
Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol (THC): A randomized crossover trial. Pharmacopsychiatry2002;
35: 57–61.
23.
Müller-VahlKRSchneiderUPrevedelHet al.
Delta-9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry2003;
64: 459–465.
24.
KanaanASJakubovskiEMüller-VahlKR.Significant tic reduction in an otherwise treatment-resistant patient with Gilles de la Tourette syndrome following treatment with nabiximols. Brain Sci2017;
7: 47
25.
TrainorDEvansLBirdR.Severe motor and vocal tics controlled with Sativex®. Australas Psychiatry2016;
24: 541–544.
26.
McPartlandJMDuncanMDi MarzoVet al.
Are cannabidiol and delta(9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic reviewBr J Pharmacol2015;
172: 737–753.
27.
NiesinkRJVan LaarMW.Does cannabidiol protect against adverse psychological effects of THC?Front Psychiatry2013;
4: 130
